Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J M Bennett

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

Leukemia

English

Proposals for the Classification of Chronic (Mature) B and T Lymphoid Leukaemias. French-American-British (FAB) Cooperative Group.

Journal of Clinical Pathology

English

Related publications

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

English

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

English

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

Clinical Lymphoma, Myeloma and Leukemia

English

Missing HLA C Group 1 Ligand in Patients With AML and MDS Is Associated With Reduced Risk of Relapse and Better Survival After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning

American Journal of Hematology

Hematology

2017

English

Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

American Journal of Hematology

Hematology

2018

English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica

Hematology

2008

English

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML

Frontiers in Pharmacology

Pharmacology

2018

English

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology

English

Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy

Mediterranean Journal of Hematology and Infectious Diseases

Infectious Diseases

Hematology

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J M Bennett

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

Proposals for the Classification of Chronic (Mature) B and T Lymphoid Leukaemias. French-American-British (FAB) Cooperative Group.

Related publications

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

Missing HLA C Group 1 Ligand in Patients With AML and MDS Is Associated With Reduced Risk of Relapse and Better Survival After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning

Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy